Adagene Inc.
corporate_fare Company Profile
Adagene Inc. (NASDAQ:ADAG) is a publicly traded company in the Life Sciences sector. Wiseek monitors ADAG SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Adagene Reports H1 2026 Results: $127.9M Cash, Runway into Late 2028, Muzastotug Phase 2 Data Expected 1H 2027
- Adagene's Muzastotug Shows 31% ORR in MSS CRC, Cash Runway Extended to Late 2028
- Adagene Reports Strong Unaudited Cash Position of $127.9 Million
- CEO Peter Luo no longer attributed beneficial ownership of 11.20% stake held by family trust
- Adagene's Muzastotug Shows Strong Efficacy and Favorable Safety in Combination Therapies for HCC and MSS CRC
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for ADAG, detected from its recent SEC filings · based on capital-structure filings through 2026-04-02.
Public Offering Priced · Significant Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
ADAG files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.